Isomorphic Labs

Isomorphic Labs is a London-based artificial intelligence company that designs small molecule and antibody drugs using deep learning models derived from the AlphaFold family of protein structure predictors. The company was incorporated on February 24, 2021 and announced publicly on November 4, 2021 as a spin-out of Google DeepMind, structured as a sister company under Alphabet rather than as a DeepMind subsidiary.^[2] It was founded and is led by Demis Hassabis, its chief executive, who shared the 2024 Nobel Prize in Chemistry with John Jumper and David Baker for the original AlphaFold work that underpins Isomorphic's technology stack. Hassabis also ran Google DeepMind until August 2026, when he became chair of Google DeepMind and chief scientist of Alphabet while remaining Isomorphic's chief executive.^[37] By May 2026 the company had raised roughly $2.7 billion in external equity (a $600 million first external round in 2025 and a $2.1 billion Series B in 2026) and signed drug-discovery partnerships with Eli Lilly, Novartis, and Johnson & Johnson.^{[13][15][16][25][43]} In October 2026 Bloomberg reported that the company was in early talks to raise new funds at a valuation of at least $40 billion; the financing had not closed.^[35]

Isomorphic occupies a distinct position in the AI drug discovery sector. Where competitors such as Recursion Pharmaceuticals, Insilico Medicine, and BenevolentAI generally combine machine learning with high-throughput phenotypic screening, knowledge graphs of biomedical literature, or generative chemistry conditioned on protein sequences, Isomorphic builds its platform around explicit structural prediction of protein-ligand and protein-protein complexes. The thesis, articulated by Hassabis and former president Colin Murdoch in 2021, is that if the same deep learning paradigm that solved the protein folding problem can be extended to the full chemistry of drug interactions, the median ten-to-fifteen year drug discovery and pre-clinical development timeline can be compressed to a fraction of that figure. As of October 2026 the company has raised approximately $2.7 billion in external capital across two rounds, signed milestone-bearing partnerships with Eli Lilly and Novartis carrying up to $2.9 billion in combined milestone payments, added a cross-modality research collaboration with Johnson & Johnson in January 2026, co-authored the AlphaFold 3 paper with Google DeepMind, described the IsoDDE drug design engine in a February 2026 technical report, and has said it expects to begin its first clinical trials by the end of 2026.^{[3][4][5][22]}

How did Isomorphic Labs get started?

The immediate trigger for Isomorphic Labs was the November 2020 release of AlphaFold 2 at the fourteenth Critical Assessment of Structure Prediction (CASP14) competition, which produced protein structure predictions of accuracy comparable to experimental crystallography and was widely described as the resolution of a fifty-year grand challenge in computational biology. DeepMind followed CASP14 by releasing predicted structures for the entire human proteome and, in partnership with the European Bioinformatics Institute, for more than two hundred million proteins through the AlphaFold Protein Structure Database. Internally, Hassabis and Colin Murdoch began to consider how the same modelling approach might be applied to small molecule and biologic design, and with a group of DeepMind employees they drew up a business plan for the company that they pitched to Alphabet.^[3][6][7]

Drug discovery is one of the most economically significant translation problems in biology. Industry estimates put the average capitalised cost of bringing a new molecular entity to market at $2 to $2.6 billion and the median timeline at twelve to fifteen years from target identification to regulatory approval, with roughly ninety percent of candidates failing in trials. Hassabis and Murdoch argued that better physical models of how candidate drugs bind to and modulate protein targets could substantially raise the prior probability of clinical success.^[8]

Isomorphic Labs was incorporated in England and Wales as Isomorphic Labs Limited on February 24, 2021 and announced publicly on November 4, 2021. The structure chosen was an Alphabet subsidiary parallel to DeepMind rather than a DeepMind subsidiary; the company later described itself as operating autonomously within Alphabet, with its own dedicated resources and an exclusive focus on applying AI to drug discovery.^[9][16] Hassabis served as chief executive of both DeepMind and Isomorphic (described in 2022 as Isomorphic's founder and acting CEO), an unusual dual-CEO arrangement that lasted until August 2026.^[28][37]

Who runs Isomorphic Labs?

Isomorphic Labs is controlled by Alphabet. According to its accounts for 2025, the UK operating company, Isomorphic Labs Limited, was at the end of 2025 a wholly owned subsidiary of Isomorphic Holdings LLC, a United States company whose controlling member is Alphabet Inc.^[39] Alphabet's percentage stake has not been disclosed; at the time of the Series B, Hassabis declined to comment on it, according to Bloomberg.^[35] The company is headquartered in London. In early 2022 its team of just over a dozen people worked from a temporary office in King's Cross.^[3] Plans for an office in Lausanne, Switzerland were reported in December 2022,^[10] and the company opened it in May 2023, first on the campus of the Ecole Polytechnique Federale de Lausanne (EPFL) and later in the city's Flon district.^[40] It established a United States site in the Kendall Square area of Cambridge, Massachusetts in June 2025, announced together with the appointment of its chief medical officer, as an operational hub drawing on the city's biomedical ecosystem.^[27] In November 2025 the company said it had grown to more than 300 employees across London, Lausanne and Cambridge.^[11]

Leadership has evolved several times as the company has scaled. At the public launch in November 2021 Hassabis was the sole named executive. Colin Murdoch, Google DeepMind's chief business officer, was part of the founding team, and in March 2024 he became the company's first president, responsible for running the business day to day while continuing as DeepMind's chief business officer.^[3][41] The first phase of the wider management team was announced on May 1, 2022: Miles Congreve joined as chief scientific officer from the same role at Sosei Heptares, Sergei Yakneen as chief technology officer from SOPHiA GENETICS (where he had been senior vice president and chief technology officer), and Max Jaderberg as director of machine learning from DeepMind, where he had led the Open-Ended Learning research team after co-founding Vision Factory, an image recognition startup acquired by Google in 2014.^[28] Jaderberg was subsequently promoted to chief AI officer, leading the research, development, and application of the company's drug design models including AlphaFold 3.^[29] Pamela Carroll, previously chief business officer at Roivant Discovery, served as chief operating officer.^[42] Yakneen, who as chief technology officer championed the Lausanne office,^[40] and Carroll do not appear on the published leadership team as of October 2026.^[30] In June 2025 the company appointed Ben Wolf, a physician-scientist specialising in precision oncology who had been chief medical officer at Relay Therapeutics and, before that, KSQ Therapeutics, as its chief medical officer, based at the new Cambridge, Massachusetts site, where he would establish a group of biomedical talent and lead the company's work translating AI-driven drug discovery into medicines.^[27]

On November 26, 2025 the company announced that Jaderberg would succeed Murdoch as president effective January 1, 2026, overseeing day-to-day operations, while Murdoch would remain a close adviser to Jaderberg and Hassabis.^[11] Hassabis remains chief executive. On August 5, 2026 Alphabet announced that Hassabis was handing over day-to-day operational responsibility for Google DeepMind to Koray Kavukcuoglu and becoming chair of Google DeepMind and chief scientist of Alphabet, while continuing to lead Isomorphic. In his note to staff Hassabis wrote that he would be "leaning into my role at Isomorphic".^[37][38] John Jumper, who led the AlphaFold 2 team at DeepMind and is a corresponding author on the AlphaFold 3 paper alongside Jaderberg and Hassabis,^[17] is not formally part of Isomorphic's leadership; he shared the 2024 Nobel Prize in Chemistry with Hassabis.

Leadership team as of October 2026

The table reflects the leadership team published on the company's website as of October 2026.^[30] The company formed a scientific advisory board in January 2023 with four Nobel laureates as its inaugural members: Jennifer Doudna, David MacMillan, Paul Nurse, and Venki Ramakrishnan.^[50] Menelas Pangalos is also listed on the board as of October 2026.^[30]

How much funding has Isomorphic Labs raised?

For its first three and a half years Isomorphic operated entirely on capital provided by Alphabet, an arrangement under which the company signed two large pharmaceutical partnerships and co-developed AlphaFold 3 without raising external equity; its UK operating company had an average headcount of 125 in 2024.^[39] The first external round was announced on March 31, 2025. Thrive Capital, the New York firm founded by Joshua Kushner that is also a major investor in OpenAI, led a $600 million round with participation from GV (the venture arm of Alphabet) and follow-on capital from Alphabet itself.^[12][43] The company described it as its first external funding round. According to TechCrunch, Hassabis told The New York Times that Isomorphic did not need the capital but that the money would help it hire top research scientists.^[12] STAT later reported that Thrive had courted the company for about 18 months, at a time when Isomorphic had kept outside investors at bay and was not actively raising money.^[48] Wilson Sonsini Goodrich and Rosati advised Isomorphic on the transaction.^[44]

In May 2026, less than fourteen months after the first external round, Isomorphic announced a Series B of $2.1 billion, again led by Thrive Capital, with participation from Temasek of Singapore, MGX of the United Arab Emirates, CapitalG (Alphabet's growth investment arm), the United Kingdom's Sovereign AI Fund, and follow-on investment from Alphabet and GV. R&D World described the round as among the largest private financings in the history of AI drug discovery.^[23] It brought total external capital to roughly $2.7 billion. The company stated that proceeds would be used to power its AI drug design engine, scale the business globally, and progress its drug candidate pipeline toward the clinic, including hiring across AI research, engineering, drug design, and clinical functions.^[13][14]

The Series B announcement included statements from Alphabet leadership and from Isomorphic's own executives. Ruth Porat, president and chief investment officer of Alphabet, said the company's trajectory was encouraging and that the funding would be used to bring interventions to market with greater speed. Hassabis framed the raise as a step toward the company's stated mission of solving all disease, saying the capital would let Isomorphic build out its drug design engine at scale. Jaderberg, by then president, said the drug design engine "works" and was giving the company a repeatable way to design new medicines for a wide range of diseases.^[24] Bloomberg later reported that Hassabis had said at the time that Alphabet provided a "large part" of the round, while declining to comment on Alphabet's stake or the company's valuation.^[35]

Company filings show two large share issues by the UK operating company to its holding company. On March 31, 2025, the day the first external round was announced, Isomorphic Labs Limited issued 94,684,382 ordinary shares to its immediate holding company, Isomorphic Holdings LLC, for total consideration of about £448.9 million, and on June 12, 2026 it issued a further 31,634,446 ordinary shares to that holding company for about £402.4 million.^[39]

Funding rounds

Isomorphic has not disclosed a valuation for either round.^[35][36][43]

Reported funding talks (October 2026)

On October 8, 2026 Bloomberg reported, citing people familiar with the effort, that Isomorphic was in early talks to raise new funds at a valuation of at least $40 billion. One of the people said the round could value the company at as much as $50 billion. The financing had not closed and details could change, and Isomorphic did not respond to Bloomberg's request for comment.^[35] The report did not give the size of the round or name any investors. Tech Funding News noted that the talks came less than five months after the Series B, for which the company had not stated a valuation.^[36]

Financial results

Isomorphic Labs Limited, the UK operating company, files annual accounts with Companies House. Its accounts for 2025 report no turnover in either 2025 or 2024. Income from the pharmaceutical collaborations is recorded as other operating income rather than revenue, because the company judged that it did not represent the output of its ordinary activities. Research and development costs are included within administration expenses.^[39]

The figures cover the UK company only. They do not include the holding company, and the average headcount differs from the company's own statement of more than 300 employees across its three sites in November 2025.^[11][39]

What are Isomorphic Labs' pharmaceutical partnerships?

Isomorphic Labs operates a hybrid business model that combines internal therapeutic programs (where the company owns the asset and bears the development risk) with collaboration agreements where it provides AI-driven target selection, hit identification, and lead optimisation services to a pharmaceutical partner in exchange for upfront payments, milestone payments, and royalties on any resulting commercial product. As of October 2026 the company has disclosed three pharmaceutical partnerships.

The first two partnerships were both announced on January 7, 2024, in advance of the JPMorgan Healthcare Conference; the Lilly announcement described that deal as Isomorphic's first pharmaceutical partnership.^[15][16] The Eli Lilly agreement involved a $45 million upfront payment, eligibility for up to $1.7 billion in performance-based milestone payments, and tiered royalties up to low double digits on net sales of any commercial product. The collaboration focused on small molecule therapeutics against multiple undisclosed targets. The Novartis agreement was structured similarly, with a $37.5 million upfront payment plus Novartis funding of select research costs, up to $1.2 billion in milestone payments, and tiered royalties from mid-single up to low double digits on net sales, covering three undisclosed targets. The combined headline value of the two deals, $2.9 billion in potential milestones plus $82.5 million in upfront payments (about $3 billion as reported by industry press), excludes royalties.^[15][16] On February 18, 2025 Isomorphic and Novartis expanded their collaboration, adding up to three additional research programs on the same financial terms as the original agreement. Fiona Marshall, president of biomedical research at Novartis, said the initial programs had deliberately selected particularly challenging targets and that the first year of work had explored chemical spaces that would be unavailable through traditional methods.^[31]

The third partnership, announced on January 20, 2026, is a cross-modality, multi-target research collaboration with Johnson & Johnson, conducted through its Janssen Biotech entity. Unlike the small-molecule-focused Lilly and Novartis deals, the Johnson & Johnson collaboration spans several modalities including small molecules, antibodies, peptides, and molecular glues, and is aimed at targets that have historically been difficult to drug. Under the agreement Isomorphic handles in silico compound design and prediction using its AI platform, while Janssen Biotech leads experimental validation and downstream development. Financial terms and the specific therapeutic categories were not disclosed. Isomorphic chief research officer Sarah Skerratt described the work as aimed at unlocking previously inaccessible areas of biology rather than simply speeding up existing pipelines.^[25][26]

Disclosed pharmaceutical partnerships

The 2025 accounts of Isomorphic Labs Limited describe the agreements as multi-target research collaboration and license agreements that apply IsoDDE to the development of small molecule therapeutics. Each agreement has collaboration targets and a research plan for every target program setting out the parties' responsibilities, and milestone payments fall due when specified program advancements are achieved. The accounts state that the company had not yet achieved any such milestones; it recognised £55.2 million of other operating income from the agreements in 2025.^[39]

How does Isomorphic Labs' technology work?

How is Isomorphic related to AlphaFold?

Isomorphic Labs' modelling effort is descended directly from the AlphaFold programme at Google DeepMind but has diverged substantially in scope and architecture. AlphaFold 2, released in 2020 and 2021, was a static protein structure predictor: given an amino acid sequence, it produced a single most likely three-dimensional conformation of the folded protein. AlphaFold 2 used a custom Evoformer block operating on multiple sequence alignments together with a structure module that produced atomic coordinates. The model was trained on the Protein Data Bank, an open archive of approximately two hundred thousand experimentally determined protein structures.

AlphaFold 3, co-authored by Isomorphic Labs and Google DeepMind and published in Nature on May 8, 2024 (volume 630, pages 493 to 500), generalised the modelling target beyond single protein chains to include the joint structure of complexes containing proteins, nucleic acids, small molecule ligands, ions, and post-translationally modified residues. The architecture replaced the Evoformer with a simpler Pairformer and introduced a diffusion-based generative head that directly generates atomic coordinates. Reported accuracy improvements were dramatic: protein-ligand interaction accuracy exceeded that of state-of-the-art docking tools, antibody-antigen prediction accuracy was substantially higher than AlphaFold-Multimer v2, and protein-nucleic acid interaction accuracy was higher than specialist predictors.^[17]

The AlphaFold 3 release was accompanied by a free public AlphaFold Server hosted by Google DeepMind that allows non-commercial researchers to submit jobs containing proteins, nucleic acids, ligands, ions, and modified residues. The server uses a slightly restricted version of the AlphaFold 3 model and applies daily query limits per user. Source code for AlphaFold 3 was not initially released with the paper, drawing criticism from segments of the scientific community and an editorial response from Nature about its code availability policies. DeepMind ultimately released the AlphaFold 3 inference code on November 11, 2024 for non-commercial use, with model weights provided on application.^[18]

What is IsoDDE, the Isomorphic Labs Drug Design Engine?

On February 10, 2026 Isomorphic Labs released a twenty-seven-page technical report describing the Isomorphic Labs Drug Design Engine, abbreviated IsoDDE. The report describes IsoDDE as a unified computational system, and the capabilities it presents include protein-ligand structure prediction, antibody-antigen interface modelling, binding affinity estimation, and ligandable pocket identification.^[45] The company has said the engine is made up of a number of proprietary AI models.^[13] The report positioned IsoDDE as a substantial advance beyond AlphaFold 3, with the model designed specifically for drug discovery rather than the more general biomolecular interaction problem that AlphaFold 3 addresses.^[19]

On the Runs N' Poses generalisation benchmark for protein-ligand structure prediction the report stated that IsoDDE more than doubles the accuracy of AlphaFold 3 on the systems least similar to the training data. On a held-out test set of 334 novel antibody-antigen complexes IsoDDE achieved 39 percent accuracy in the high-fidelity regime defined as DockQ greater than 0.8, which the report described as a 2.3-fold improvement over AlphaFold 3 and a 19.8-fold improvement over Boltz-2 (implying roughly 17 percent and 2 percent respectively). On binding affinity estimation IsoDDE exceeded the accuracy of gold-standard physics-based free energy perturbation methods at a small fraction of the computational cost. On pocket identification IsoDDE was reported to recapitulate the recent experimental discovery by Dippon et al. of a novel cryptic binding site on the E3 ligase cereblon, identifying both the canonical and the cryptic pockets using only the amino acid sequence as input.^[20][45]

The IsoDDE release drew commentary from senior figures in computational biology. Mohammed AlQuraishi, a computational biologist at Columbia University who works on open-source versions of AlphaFold, told Nature that IsoDDE was "a major advance, on the scale of an AlphaFold4", adding: "The problem, of course, is that we know nothing of the details." Jaderberg told Nature that the models behind IsoDDE were "profoundly different" from other efforts, but that the company had no plans to reveal the 'secret sauce' behind them.^[46] Unlike the AlphaFold 3 release, IsoDDE was not accompanied by a code release or a server; the model is internal infrastructure for Isomorphic and for its partners and is not available to the broader research community.^[21]

How does IsoDDE search for new molecules?

On September 29, 2026, Isomorphic Labs described an autonomous molecular-design workflow using IsoDDE. Drug designers specify a biological target, molecule type, desired mechanism, selectivity, and properties such as solubility and cell permeability. A design agent generates molecules in successive batches and evaluates them with the company's predictive models, balancing exploration of chemical space with refinement of promising candidates.^[33]

The company illustrated computational searches lasting 2-4 days, after which researchers selected diverse compounds for synthesis and laboratory testing. It reported concentration-response measurements showing activity against the intended biological target. The demonstration concerns molecule design and laboratory activity rather than clinical outcomes in patients.^[33]

Key technical milestones

When will Isomorphic Labs have a drug in clinical trials?

Isomorphic Labs has consistently declined to provide detailed disclosure of its internal pipeline, citing competitive sensitivity. The company has stated publicly that its internal programs are primarily focused on oncology and immunology, and has indicated that it is pursuing both small molecules and antibody-based modalities.^[3][43] Detailed target lists, mechanisms of action, and indication-level disclosures have not been provided.

Clinical progress has been a focal point of public attention. In 2025 Hassabis said the company would have AI-designed drugs in clinical trials by the end of that year. That timeline was not met. Speaking at an event during the World Economic Forum meeting in Davos on January 20, 2026, Hassabis said Isomorphic expected to have its first clinical trials by the end of 2026, which Reuters reported as a delay.^[22] At the time of the May 2026 Series B, no human patient had been dosed with an Isomorphic-designed compound, according to R&D World.^[23] In a September 2026 essay the company said its preclinical data was "helping us to gear up for clinical developments".^[33] In October 2026 Tech Funding News reported that the company still expected its first candidates to enter human trials before the end of 2026.^[36]

Clinical timeline

Bloomberg noted in October 2026 that, while AI developers promise to cut the time and cost of developing drugs, few have progressed to clinical trials and none have brought a medicine to market.^[35]

What is Isomorphic Labs' role in biosecurity?

On July 16, 2026 Isomorphic Labs and Google DeepMind published a joint approach to bioresilience, addressing both the prevention of model misuse and the application of their systems to outbreak preparedness. The companies said they had advanced more than 15 partnerships with government bodies, biosecurity organizations, and research groups over the preceding 12 months, and organised the work around three areas: prevention, detection, and response.^[32]

On prevention, the statement describes a four-step safety process (threat modeling, evaluations, mitigations, and monitoring) applied to models such as Gemini, along with work on adapting the SynthID watermarking technology to biology so that DNA synthesis providers could screen for potentially risky AI-generated biological sequences; the effort sits within DeepMind's Frontier Safety Framework approach to chemical, biological, radiological, and nuclear risks. On detection, the companies cite AlphaEvolve optimising the algorithms used to produce and analyse metagenomic sequencing data for pathogen surveillance, and exploratory work on using AlphaGenome to help characterise pathogens from sequence data. On response, Isomorphic said it has established a focused unit to rapidly deploy its drug design engine to design medical countermeasures for governments and non-profit organisations during novel outbreaks, covering both naturally occurring pandemics and potential risks arising from the misuse of advanced AI.^[32]

What is Isomorphic Labs' role in the Virtual Biology Initiative?

On October 7, 2026, Isomorphic Labs announced that it was a founding member of the Virtual Biology Initiative, an international effort convened by Biohub. The collaboration aims to generate and make accessible biological data for predictive AI models. Participating organizations are committing funding, data, computation, and new measurement technology to an intended open resource for the research community.^[34] According to the announcement, the participating organizations were together investing $1.8 billion in funding, data, computation and new measurement technology, and, in addition, Google DeepMind, Isomorphic Labs and Meta were collectively investing $300 million in the initiative; Jaderberg said Isomorphic was helping to build "a massive, multimodal data foundation".^[47]

How does Isomorphic compare to other AI drug discovery companies?

Isomorphic Labs operates in a sector with several established competitors. Recursion Pharmaceuticals, founded in 2013 and headquartered in Salt Lake City, has built an industrial-scale phenotypic screening platform that perturbs cells with hundreds of thousands of genetic and chemical interventions and applies deep learning to derive disease hypotheses across many indications in parallel. Recursion went public in 2021 and merged with Exscientia in 2024. Insilico Medicine, founded in 2014, pioneered generative chemistry models for de novo small molecule design, and in December 2021 announced that it had dosed the first healthy volunteer in a first-in-human microdose trial of ISM001-055, an AI-discovered candidate for idiopathic pulmonary fibrosis.^[49] BenevolentAI applies a knowledge-graph approach integrating published biomedical literature with experimental data, most notably identifying baricitinib as a candidate treatment for COVID-19 in early 2020.

The distinctive feature of Isomorphic Labs relative to these companies is the explicit centrality of structural prediction of binding geometry in its design loop. Where Recursion derives candidate hits from cellular phenotypes, Insilico from generative chemistry conditioned on protein sequences, and BenevolentAI from textual and graph-based associations, Isomorphic centres its workflow on predicted atomistic structures of protein-ligand complexes that are validated against experimental crystallography and cryo-electron microscopy data. The approach is closer in spirit to traditional structure-based drug design but operates at substantially larger scale and with substantially higher predictive accuracy than the docking and free-energy tools that have historically dominated that subfield. The trade-off is that Isomorphic's approach is most natural for targets that admit a single binding pocket and a well-defined functional readout, while phenotypic platforms can in principle uncover new biology even when target identity is unknown.

What criticism has Isomorphic Labs faced?

Academic and industry reception of Isomorphic Labs' technical output has been broadly enthusiastic. The 2024 Nobel Prize in Chemistry awarded jointly to Hassabis, Jumper, and David Baker is the highest-profile validation of the AlphaFold programme and, by extension, of the scientific premise underlying Isomorphic. The AlphaFold 3 paper has accumulated thousands of citations within its first two years, and the IsoDDE report drew positive technical commentary from academic computational biologists.

Criticism has tended to focus on three issues. The first is code availability: the original AlphaFold 3 paper was published without source code, which generated an open letter from a section of the structural biology community and an editorial from Nature acknowledging the issue. The eventual November 2024 code release under a non-commercial licence partially addressed the criticism but did not satisfy advocates of fully open scientific release. The second is the gap between technical capability and clinical evidence. As of October 2026 Isomorphic had not reported human efficacy or safety data for any internally designed compound, and several observers have noted that the historical correlation between pre-clinical predictive accuracy and clinical success is weaker than commonly assumed because of the role of unanticipated toxicity, pharmacokinetics, and disease biology that even excellent structural models do not address. The third is the question of independence from Alphabet: Isomorphic's continued reliance on Alphabet for core compute, sister-company collaboration with DeepMind, and partial financing through the GV and CapitalG arms of Alphabet has raised questions about the company's effective autonomy and the long-term direction it would pursue if Alphabet's strategic priorities shifted. The reported October 2026 valuation talks drew similar comment; Tech Funding News observed that a valuation near $40 billion would assume a great deal about medicines not yet proven in people.^[36]

Outlook and significance

As of October 2026 Isomorphic Labs is one of the most heavily capitalised and technically credentialed AI-native drug discovery companies in the world. The Eli Lilly, Novartis, and Johnson & Johnson collaborations, the $2.7 billion of disclosed external equity capital, the Nobel-laureate-led management team, and the demonstrated technical advances embodied in AlphaFold 3 and IsoDDE place the company in a small group of clear leaders in the application of frontier AI to pharmaceutical research. The principal open question is whether the technical advances translate to clinical and ultimately commercial success on a timeline that justifies the capital and attention deployed. The company's stated goal of beginning clinical trials before the end of 2026 is the most important near-term milestone. If Isomorphic-designed compounds prove safe and efficacious in early-phase trials over the subsequent two to three years, the company will have established a new template for drug discovery. If they do not, the company will have demonstrated the limits of pure structural prediction as a route to therapeutic value and will face a more difficult conversation about its long-term business model.^[23]

Continue reading

• IsoDDEIsoDDE, short for Isomorphic Labs Drug Design Engine, is a unified computational drug design system developed by Isomorphic Labs, the Alphabet subsidiary spun out of Google DeepMind in 2021.Mentioned 20 times above
• LList of neolabsThis list of neolabs covers the 106 companies on "The Ultimate Neolab List", a list kept by Debarghya "Deedy" Das, a partner at the venture capital firm Menlo Ventures.Listed in See also
• NNeolabA neolab, also written neo-lab or NeoLab, is an informal term for an AI research company organized around a technical research program.Listed in See also
• AAI in drug discoveryAI in drug discovery (also called AI drug discovery) is the application of artificial intelligence, machine learning, deep learning, generative models, and natural language processing across the pharmaceutical…Listed in See also
• Chai DiscoveryChai Discovery is an American AI biotechnology company that builds foundation models for predicting and designing the three-dimensional structures of biomolecules to accelerate drug discovery.Listed in See also
• Xaira TherapeuticsXaira Therapeutics is an American AI-driven drug discovery company based in South San Francisco, California, that launched publicly on April 23, 2024 with more than $1 billion in committed capitalListed in See also

More from See also

• Latent Labs
• Waypoint Bio
• Synchron
• Qventus
• Tennr
• Enveda
• Formation Bio

Topics:AI CompaniesDrug DiscoveryGoogle DeepMindHealthcare AI

References

1. "Isomorphic Labs", Wikipedia, accessed May 2026.
2. ^Isomorphic Labs, "Introducing Isomorphic Labs", November 2021. isomorphiclabs.com/...introducing-isomorphic-labs
3. ^1 ^2 ^3 ^4 ^5CNBC, "Inside Isomorphic Labs, the secretive AI life sciences startup spun off from Google DeepMind", April 9, 2025. cnbc.com/...gle-deepminds-ai-life-sciences-spinoff
4. ^Sifted, "DeepMind spinout Isomorphic Labs raises $2.1bn", May 13, 2026.
5. ^Isomorphic Labs, "Isomorphic Labs announces Series B investment round", May 12, 2026. isomorphiclabs.com/...es-series-b-investment-round
6. ^Jumper, J., Evans, R., Pritzel, A., et al., "Highly accurate protein structure prediction with AlphaFold", Nature, vol. 596, pp. 583 to 589, 2021.
7. ^AlphaFold Protein Structure Database, European Bioinformatics Institute, alphafold.ebi.ac.uk.
8. ^Tufts Center for the Study of Drug Development, "Cost of developing a new drug" annual reports, 2014 through 2024.
9. ^Companies House, Isomorphic Labs Limited, company number 13223825, incorporation date February 24, 2021. find-and-update.company-information.service.gov.uk/...13223825
10. ^Aaron Hurst, Information Age, "DeepMind spin-off Isomorphic Labs announces drug discovery scale plans", December 5, 2022. information-age.com/...overy-scale-plans-123500895
11. ^1 ^2 ^3Isomorphic Labs, "Isomorphic Labs to appoint Max Jaderberg as President", November 26, 2025. isomorphiclabs.com/...t-max-jaderberg-as-president
12. ^1 ^2TechCrunch, "Alphabet's AI drug discovery platform Isomorphic Labs raises $600M from Thrive", March 31, 2025. techcrunch.com/...hic-labs-raises-600m-from-thrive
13. ^1 ^2 ^3PR Newswire, "Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine", May 12, 2026. prnewswire.com/...-ai-drug-design-engine-302769674
14. ^Tech.eu, "Isomorphic Labs lands $2.1BN investment", May 13, 2026.
15. ^1 ^2 ^3PR Newswire, "Isomorphic Labs announces strategic multi-target research collaboration with Lilly", January 7, 2024. prnewswire.com/...llaboration-with-lilly-302027392
16. ^1 ^2 ^3 ^4PR Newswire, "Isomorphic Labs announces strategic multi-target research collaboration with Novartis", January 7, 2024. prnewswire.com/...boration-with-novartis-302027387
17. ^1 ^2Abramson, J., Adler, J., Dunger, J., et al., "Accurate structure prediction of biomolecular interactions with AlphaFold 3", Nature, vol. 630, pp. 493 to 500, May 8, 2024.
18. ^Retraction Watch, "Nature earns ire over lack of code availability for Google DeepMind protein folding paper", May 14, 2024.
19. ^Isomorphic Labs, "The Isomorphic Labs Drug Design Engine unlocks a new frontier beyond AlphaFold", February 10, 2026. isomorphiclabs.com/...ngine-unlocks-a-new-frontier
20. ^Clinical Laboratory International, "Isomorphic Labs unveils IsoDDE, a unified AI drug design engine surpassing AlphaFold 3 in biomolecular prediction", February 2026.
21. ^Winbuzzer, "Isomorphic Labs New AI Doubles AlphaFold 3's Accuracy in Protein-Ligand Predictions", February 11, 2026.
22. ^1 ^2 ^3 ^4Reuters, "Google-backed Isomorphic Labs delays clinical trial timeline", January 20, 2026 (via Yahoo Finance). finance.yahoo.com/...d-ai-drug-discovery-195423147
23. ^1 ^2 ^3 ^4R and D World Online, "Alphabet-spinoff Isomorphic Labs raises $2.1 billion in quest to solve all disease with AI-based drug discovery tools", May 12, 2026. rdworldonline.com/...ai-based-drug-discovery-tools
24. ^Fierce Biotech, "Alphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model", May 13, 2026. fiercebiotech.com/...el-next-gen-drug-design-model
25. ^1 ^2Isomorphic Labs, "Isomorphic Labs enters into a research collaboration with Johnson & Johnson", January 20, 2026. isomorphiclabs.com/...oration-with-johnson-johnson
26. ^Pharmaphorum, "J&J bets on Isomorphic for AI-powered drug hunt", January 2026. pharmaphorum.com/...somorphic-ai-powered-drug-hunt
27. ^1 ^2Isomorphic Labs, "Isomorphic Labs appoints Dr. Ben Wolf as Chief Medical Officer and establishes US Presence", June 17, 2025. isomorphiclabs.com/...-and-establishes-us-presence
28. ^1 ^2Isomorphic Labs, "Isomorphic Labs announces first phase of management team", May 1, 2022. isomorphiclabs.com/...rst-phase-of-management-team
29. ^Isomorphic Labs, "Max Jaderberg, PhD", team biography, accessed August 2026. isomorphiclabs.com/...max-jaderberg-phd
30. ^1 ^2 ^3Isomorphic Labs, "Our Team", accessed October 2026. isomorphiclabs.com/our-team
31. ^Isomorphic Labs, "Isomorphic Labs announces Novartis collaboration expansion", February 18, 2025. isomorphiclabs.com/...rtis-collaboration-expansion
32. ^1 ^2Google DeepMind and Isomorphic Labs, "Our approach to bioresilience", July 16, 2026. deepmind.google/...our-approach-to-bioresilience
33. ^1 ^2 ^3 ^4 ^5Isomorphic Labs, "Building a new path to make medicines with AI", September 29, 2026.
34. ^1 ^2Isomorphic Labs, "Isomorphic Labs joins the Virtual Biology Initiative to build foundational data for AI models to predict and treat disease", October 7, 2026.
35. ^1 ^2 ^3 ^4 ^5 ^6Mark Bergen, Natasha Mascarenhas, Rebecca Torrence and Ed Ludlow, Bloomberg, "Alphabet's Isomorphic Labs in Funding Talks for at Least $40 Billion Value", October 8, 2026 (syndicated by Yahoo Finance; original at bloomberg.com/...lks-for-at-least-40-billion-value).
36. ^1 ^2 ^3 ^4Tech Funding News, "DeepMind spinout Isomorphic Labs eyes $40B valuation less than five months after $2.1B round: Report", October 9, 2026.
37. ^1 ^2 ^3Sundar Pichai and Demis Hassabis, Google, "The next chapter of our AI momentum", August 5, 2026.
38. ^Fortune, "Demis Hassabis steps down from Google DeepMind CEO role amid a major AI leadership shake-up", August 5, 2026.
39. ^1 ^2 ^3 ^4 ^5 ^6Isomorphic Labs Limited, "Annual report and financial statements for the year ended 31 December 2025", Companies House, company number 13223825, filed October 2, 2026.
40. ^1 ^2Isomorphic Labs, "Inside Isomorphic Labs' Lausanne office", November 13, 2025.
41. ^Isomorphic Labs, "In conversation with... Colin Murdoch, Isomorphic Labs' first President", March 11, 2024.
42. ^The Mark Foundation for Cancer Research, "Pamela Carroll, PhD", accessed October 2026.
43. ^1 ^2 ^3 ^4 ^5PR Newswire, "Isomorphic Labs announces $600 million funding to further develop its next-generation AI drug design engine and advance therapeutic programs into the clinic", March 31, 2025.
44. ^Wilson Sonsini Goodrich and Rosati, "Wilson Sonsini Advises Isomorphic Labs on $600 Million External Funding Round", 2025.
45. ^1 ^2Isomorphic Labs Team, "Accurate Predictions of Novel Biomolecular Interactions with IsoDDE", technical report, February 10, 2026.
46. ^Ewen Callaway, Nature, "'An AlphaFold 4': scientists marvel at DeepMind drug spin-off's exclusive new AI", February 19, 2026 (reproduced by Scientific American; original at nature.com/...d41586-026-00365-7).
47. ^Biohub, "International, cross-sector collaboration commits nearly $2 billion to build foundational data for AI models to predict and treat disease", news release, October 7, 2026.
48. ^Allison DeAngelis, STAT, "Does Isomorphic Labs have what it takes to revolutionize drugmaking?", October 19, 2026.
49. ^Insilico Medicine (via HKSTP), "Insilico Medicine Initiates First-in-Human Study of ISM001-055, A Novel Drug Discovered Using Insilico's Proprietary End-to-end Artificial Intelligence Platform", December 1, 2021.
50. ^PR Newswire, "Isomorphic Labs announces Scientific Advisory Board", January 9, 2023.

Show all 50 references